This exploratory analysis characterizes transcriptional differences among response groups and identifies candidate genes and pathways that may contribute to vincristine sensitivity or resistance in CTVT. Considering the small number of resistant tumors included, these results are preliminary and require validation in larger, independent cohorts.

In silico drug sensitivity analysis further suggested that high-risk patients may develop poorer sensitivity to five clinical drugs, including Cisplatin, Oxaliplatin, and Vinorelbine. The six-m7G-related-lncRNA signature represents a promising prognostic tool for EGC that may facilitate personalized risk stratification and guide clinical decision-making regarding adjuvant or immunotherapeutic strategies.

These findings indicate that vinorelbine-based regimens inhibit tumor spheroid growth predominantly through cytostatic mechanisms rather than induction of apoptosis. This non-apoptotic growth-control strategy may be relevant for the management of apoptosis-resistant endometrial cancer.

It was demonstrated that the IONPs primarily bound to the membrane of Jurkat cells and formed ordered assembly structures under MF, which disrupted cellular homeostasis by activating the calcium-NFAT-FasL signaling pathway, hyperpolarizing mitochondria, reprogramming metabolism, and disrupting cytoskeletal assembly. In conclusion, the MAMS strategy sensitized Jurkat cells to VCR by multilevel interference with the homeostasis of cells, providing a promising approach for developing more effective and less cytotoxic T-ALL treatment regimens.

We constructed and verified a four-gene ORS-based prognosis model for GBM, linking replication stress to immune evasion and drug sensitivity for the first time. Experimental validation confirmed the pro-tumorigenic role of PDCL3, offering potential biomarkers and therapeutic targets.

Adjuvant atezolizumab with cisplatin and vinorelbine did not significantly improve DFS compared with patients with resected EGFR-mutated NSCLC. These results highlight the limited benefit of immune checkpoint inhibitors in this population and the need for predictive biomarkers to guide immunotherapy strategies for improving cure rates.

Vincristine is a well-characterized substrate of ABCB1 and ABCC1 and thus serves as a mechanistic probe to model transporter-driven multidrug resistance in a CRC cellular background...These cell lines provide useful models for developing strategies to overcome drug resistance in CRC. Because ABCB1 and ABCC1 are dynamically regulated during tumor evolution and therapeutic pressure, these models capture a heritable transporter-driven component of multidrug resistance.

P=N/A, N=40, Recruiting, Children's National Research Institute | Trial completion date: Dec 2025 --> May 2027 | Trial primary completion date: Sep 2025 --> May 2026

The IL-33/ST-2 signaling pathway contributes to the pathogenesis of hepatic fibrosis and immunological dysregulation in AE by influencing eosinophil function. Combined intervention targeting this pathway and albendazole administration confers enhanced therapeutic efficacy for AE, encompassing antifibrotic action, liver function recovery, and immune modulation.

Considering the presence of mediastinal lymph node involvement and programmed death-ligand 1 expression, the patient received four courses of cisplatin and vinorelbine, followed by treatment with atezolizumab. Programmed death-ligand 1-positive typical carcinoids are associated with a higher frequency of lymph node metastasis and poorer prognosis. Additional case investigations are required to assess the efficacy of immune checkpoint inhibitors in typical carcinoid.

In-vivo studies conducted on Balb/c mice showed reduced Psoriasis Area Severity Index, Spleen weight as well as reduced keratinocyte proliferation in histopathological studies. In conclusion, developed novel formulation of Albendazole reduced keratinocyte proliferation making it a possible effective strategy in the management of psoriasis.

A combination of the ΔVFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests that vinorelbine is a promising agent to combine with oncolytic vaccinia virus for the management of ovarian cancer.